Therapy Detail

Therapy Name IPI-549
Synonym
Therapy Description

IPI-549 is a selective PI3Kgamma inhibitor that enhances anti-tumor immune response and inhibits tumor growth in animal models (Cancer Immunol Res January 2016 4; B029).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
IPI-549 PIK3CG inhibitor 8 IPI-549 is a selective PI3Kgamma inhibitor that enhances anti-tumor immune response and inhibits tumor growth in animal models (Cancer Immunol Res January 2016 4; B029).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable IPI-549 Preclinical Actionable In a preclinical study, IPI-549 inhibited tumor growth in multiple xenograft models of solid tumors (Mol Cancer Ther December 2015 14; A192). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02637531 Phase I Pembrolizumab IPI-549 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Recruiting
NCT03795610 Phase II IPI-549 Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma Not yet recruiting